Philip Lee advised Novellus on the deal.Brooklyn ImmunoTherapeutics has completed its acquisition of engineered cellular medicine company Novellus Therapeutics Limited. This acquisition advances Brooklyn’s evolution into…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
